JT Gains World-First Topical JAK Inhibitor Approval
Japan Nod In Competitive Dermatitis Space
Executive Summary
Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance for a new contender in the large prostate cancer space.
You may also be interested in...
Atopic Dermatitis: Ruxolitinib And Baricitinib Spearheading New Therapies
Top-line Phase III results from Incyte’s TruE-AD2 study of ruxolitinib cream and Eli Lilly’s BREEZE-AD4 and BREEZE-AD5 studies of oral baricitinib show that the compounds achieved primary endpoints in atopic dermatitis, and they may eventually challenge Sanofi’s Dupixent’s growth in the sector.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen’s Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca.